The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day

Figures & data

Figure 1 Pathological section of tumor formed 3 weeks after the inoculation of Tca8113 cells into the cheek of nude mice (hematoxylin and eosin stain, ×200).

Table 1 Drug efficacy and adverse reactions in control and experimental tumor-bearing mice 7 days after L-OHP injection

	Control group	L-OHP treatment groups
		4 HALO	10 HALO	16 HALO	22 HALO
Tumor inhibition rate (%)	0.00	23.97	7.05	31.55	28.33
Survival time (days), mean ± SD	9.85 ± 2.80	14.07 ± 4.02	10.73 ± 3.51	20.73 ± 5.41	17.33 ± 6.11
WBC count (10^3 cells/μL), mean ± SD	16.54 ± 0.20	14.34 ± 0.23	14.18 ± 0.25	15.40 ± 0.2	14.98 ± 0.18
Body weight (g), mean ± SD	17.32 ± 0.12	17.48 ± 0.07	17.35 ± 0.10	17.91 ± 0.18	17.55 ± 0.13
Perianal swelling (%) [n/15]	0.00 [0/15]	46.67 [7/15]	60.00 [9/15]	13.33 [2/15]	26.67 [4/15]

Abbreviations: L-OHP, oxaliplatin; HALO, hours after light onset; WBC, white blood cell; SD, standard deviation.

Figure 2 Cosine fitting curve of the survival times of tumor-bearing mice injected with L-OHP at four different time points.

Notes: The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average survival time in each group (n = 15) of tumor-bearing mice that received L-OHP at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance, F = 15.02, P < 0.001; circadian rhythm was tested with cosine analysis, F = 12.47, P < 0.001.
Abbreviations: L-OHP, oxaliplatin; HALO, hours after light onset.

Figure 3 Cosine fitting curve of the WBC counts of tumor-bearing mice injected with L-OHP at four different time points.

Notes: The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average WBC counts in each group (n = 15) of tumor-bearing mice at 22 HALO 7 days after L-OHP injection at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance, F = 292.21, P < 0.001; circadian rhythm was tested with cosine analysis, F = 100.25, P = 0.00.
Abbreviations: L-OHP, oxaliplatin; HALO, hours after light onset; WBC, white blood cell.

Figure 4 Cosine fitting curve of the body weights of tumor-bearing mice injected with L-OHP at four different time points.

Notes: The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average body weight in each group (n = 15) of tumor-bearing mice at 22 HALO 7 days after L-OHP injection at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance, F = 51.87, P < 0.001; circadian rhythm was tested with cosine analysis, F = 24.61, P = 0.00.
Abbreviations: L-OHP, oxaliplatin; HALO, hours after light onset.